GlassScriptPhysician profile
Kiumars Bakshandeh
NPI 1700945144
$2,212.80
in general payments reported to CMS, 2019-2025
16 companies · $393 in 2025
The $393 reported for 2025 was more than what 75% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $553 · 2020: $429 · 2021: $294 · 2022: $235 · 2023: $220 · 2024: $89.57 · 2025: $393.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $702.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $702.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $435.40 | 2019-2025 | Winlevi |
| Abbvie INC. | $427.41 | 2019-2024 | |
| Pfizer INC. | $249.54 | 2019-2020 | |
| Procept Biorobotics Corporation | $166.92 | 2025 | |
| Galderma Laboratories, L.P. | $166.64 | 2021-2023 | Aklief, Twyneo, Oracea |
| Epi Health, LLC | $149.69 | 2019-2021 | |
| Journey Medical Corporation | $143.74 | 2022-2025 | |
| Astellas Pharma US INC | $119.14 | 2019 | |
| Incyte Corporation | $114.88 | 2022-2025 | Opzelura |
| Janssen Biotech, INC. | $62.37 | 2022-2024 | Tremfya |
| Leo Pharma INC. | $59.09 | 2019-2023 | Adbry |
| Genzyme Corporation | $44.13 | 2025 | |
| Aclaris Therapeutics, INC. | $23.55 | 2019 | |
| Verrica Pharmaceuticals INC. | $20.26 | 2025 | Ycanth |
| Myriad Genetic Laboratories, INC. | $18.79 | 2023 | Prolaris |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermira, INC. | $11.25 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kiumars Bakshandeh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.